BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 6232320)

  • 1. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of the integrity of the inter-heavy-chain disulphide bond of rabbit IgG in the activation of the alternative pathway of human complement by the F(ab')2 region of rabbit IgG antibody in immune aggregates.
    Gadd KJ; Reid KB
    Immunology; 1981 Jan; 42(1):75-82. PubMed ID: 6780451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
    Antón LC; Alcolea JM; Sánchez-Corral P; Marqués G; Sánchez A; Vivanco F
    Biochem J; 1989 Feb; 257(3):831-8. PubMed ID: 2784671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakdown of C3 covalently bound to F(ab')2 immune complexes after complement activation by the alternative pathway.
    Antón LC; Alcolea JM; Marqués G; Sánchez-Corral P; Vivanco F
    Complement; 1986; 3(2):53-62. PubMed ID: 3769463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of complement amplification by F(ab')(2)-containing immune complexes and naturally occurring anti-hinge antibodies, possible role in systemic inflammation.
    Lutz HU; Fumia S
    Autoimmun Rev; 2008 Jun; 7(6):508-13. PubMed ID: 18558371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solubilization of immune precipitates by six isolated alternative pathway proteins.
    Fujita T; Takata Y; Tamura N
    J Exp Med; 1981 Dec; 154(6):1743-51. PubMed ID: 6459396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The covalent interaction of C3 with IgG immune complexes.
    Vivanco F; Muñoz E; Vidarte L; Pastor C
    Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.
    Zhang W; Lachmann PJ
    Immunology; 1994 Jan; 81(1):137-41. PubMed ID: 8132210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
    Fischer E; Appay MD; Cook J; Kazatchkine MD
    J Immunol; 1986 Feb; 136(4):1373-7. PubMed ID: 2418113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of rat complement by soluble and insoluble rat IgA immune complexes.
    Rits M; Hiemstra PS; Bazin H; Van Es LA; Vaerman JP; Daha MR
    Eur J Immunol; 1988 Dec; 18(12):1873-80. PubMed ID: 3220102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.
    Aguado MT; Mannik M
    Immunology; 1987 Feb; 60(2):255-60. PubMed ID: 3817872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.
    Muñoz E; Vidarte L; Casado MT; Pastor C; Vivanco F
    Int Immunol; 1998 Feb; 10(2):97-106. PubMed ID: 9580208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human erythrocytes inhibit complement-mediated solubilization of immune complexes.
    Dorval BL; Cosio FG; Birmingham DJ; Hebert LA
    J Immunol; 1989 Apr; 142(8):2721-7. PubMed ID: 2522967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.